 Latest
News
| October 27, 2008 |
MBC Pharma, Inc. awarded an SBIR Phase
II grant ($758,000) to investigate new compounds for multiple myeloma (more)
|
| November 30, 2007 |
MBC Pharma secures $1.8M in private
financing
|
| June 29, 2007 |
MBC Pharma conducts a successful
pre-IND meeting with FDA to validate development plan for MBC-11 for
treatment of Cancer Induced Bone Diseases |
| June 6, 2007 |
MBC Pharma received $100,000 NIH SBIR
grant "Novel bisphosphonates for prostate cancer therapy" |
| March, 2006 |
MBC Pharma presents latest results on vtamin B6 derivative of
alendronate (MBC-31) on Eighth and Valedictory Workshop on
Bisphosphonates, Davos, Switzerland, March 22-24, 2006
|
| January, 2006 |
MBC Pharma
newsletter |
| May 24, 2005 |
MBC Pharma awarded US Patent 6,896,781 B2 |
| April 1, 2005 |
Mayo
Clinic and MBC Pharma submit phase 2 STTR grant application to NIH
entitled "Novel bisphosphonates for breast cancer therapy" |
| March 20, 2005 |
Mayo
Clinic presents results of STTR funded study "Novel Bisphosphonates for
Multiple Myeloma therapy" at the Vth International Conference On
Cancer-Induced Bone Disease (CIBD), Davos, Switzerland |
|
|
|
Recent
Publications
- Mikko Ora, Tuomas Lonnberg, Diana Florea-Wang, Shawn
Zinnen,Alexander Karpeisky, and Harri Lonnberg (2008)
Bisphosphonate Derivatives of Nucleoside Antimetabolites:
Hydrolytic Stability and Hydroxyapatite Adsorption of
5′-b,γ-Methylene and
5′-b,γ-(1-Hydroxyethylidene) Triphosphates of
5-Fluorouridine and ara-Cytidine. JOC,
73,
4123-30
- Zinnen,
S.,Sebesta, D., Karpeisky, A., Guzaev, A., (2006) Novel vitamin B6
derivative of alendronate rapidly absorbed following oral
administration. Bone 38, S64
- Reinholz,
M., Reinholz, G., Arendt, B., Jelinek, D., Kitzmann, K., Dingli, D.,
Russel, S., W., L., and Karpeisky, A. (2005). Novel bisphosphonate
conjugates inhibit multiple myeloma cell proliferation in vitro and
increase bone mineral density and prolong survival in a mouse multiple
myeloma model. Cancer Treatment Reviews 31, abstract
# 119.
- Reinholz,
M., Reinholz, G., Jonart, L., Yoneda, T., Spelsberg, T., Lingle, W.,
and Karpeisky, M. (2004). Novel bisphosphonate conjugates decrease
metastatic bone tumor burden in the 4T1/luc mouse model of breast
cancer. Journal of Bone and Mineral Research 19, S66.
- Reinholz,
M., Jonart, L., Reinholz, G., Spelsberg, T., Lingle, W., Yoneda, T.,
and Karpeisky, M. (2004). The effects of novel bisphosphonate
conjugates on primary breast tumor burden and soft organ metastases in
the 4T1/luciferase mouse model of breast cancer. Breast Cancer
Research and Treatment 88, S133.
- Reinholz,
G.G., Getz, B., Sanders, E.S., Karpeisky, M.Y., Padyukova, N.,
Mikhailov, S.N., Ingle, J.N., and Spelsberg, T.C. (2002). Distinct
mechanisms of bisphosphonate action between osteoblasts and breast
cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Research and Treatment 71,
257-268
|
|
